Lisa A. Jackson, MD, MPH
“Kaiser Permanente Washington gives us nearly unlimited potential to address vaccine effectiveness and safety questions of national and international importance.”
Lisa A. Jackson, MD, MPH
Senior Investigator, Kaiser Permanente Washington Health Research Institute
Physician, Washington Permanente Medical Group, Internal Medicine
Biography
Lisa A. Jackson, MD, MPH, is an internist and infectious disease epidemiologist who has conducted clinical and epidemiologic studies of vaccine safety and efficacy since 1991.
Dr. Jackson is the principal investigator (PI) of KPWHRI’s Vaccine and Treatment Evaluation Unit — one of 10 network sites that the National Institutes of Health (NIH) sponsors. In this role, she leads the phase 1 clinical trial of the COVID-19 vaccine co-developed by Moderna and NIH. Launched in March 2020, this trial was the first in the world to begin testing a COVID-19 vaccine. She is also leading the phase 3 clinical trials of the COVID-19 vaccines developed by Moderna and NIH and by Janssen Pharmaceutical Companies, part of Johnson & Johnson, at KPWHRI.
Additionally, Dr. Jackson serves as KPWHRI’s principal investigator in the Vaccine Safety Datalink Project (VSDP). Sponsored by the Centers for Disease Control and Prevention (CDC), VSDP conducts ongoing research on the safety of licensed vaccines in routine use.
Dr. Jackson has written more than 200 peer-reviewed publications and 14 book chapters. She is a past member of the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee and the National Vaccine Program Office’s National Vaccine Advisory Committee.
After receiving her medical degree from the University of Virginia School of Medicine, in Charlottesville, Dr. Jackson earned her Master of Public Health (MPH) degree at the University of Washington (UW) School of Public Health. She completed her internal medicine residency training at the UW School of Medicine and served as an epidemic intelligence officer and preventive medicine resident at the CDC.
Research interests and experience
Vaccines & Infectious Diseases
Vaccine safety; COVID-19 vaccine safety and effectiveness; influenza vaccine effectiveness in the elderly; methodologic issues in vaccine effectiveness evaluations; pneumococcal polysaccharide vaccine effectiveness; pneumococcal conjugate vaccine immunogenicity in the elderly; epidemiology of E. coli bacteremia; epidemiology of community-acquired pneumonia
Recent publications
Imrey PB, Jackson LA, Ludwinski PH, England AC 3rd, Fella GA, Fox BC, Isdale LB, Reeves MW, Wenger JD. Meningcoccal carriage, alcohol consumption, and campus bar patronage in a serogroup C meningococcal disease outbreak. J Clin Microbiol. 1995;33(12):3133-7. PubMed
Kuo CC, Jackson LA, Campbell LA, Grayston JT. Chlamydia pneumoniae (TWAR). Clin Microbiol Rev. 1995;8(4):451-61. PubMed
Jackson LA, Hilsdon R, Farley MM, Harrison LH, Reingold AL, Plikaytis BD, Wenger JD, Schuchat A. Risk factors for group B streptococcal disease in adults. Ann Intern Med. 1995;123(6):415-20. PubMed
Jackson LA, Schuchat A, Gorsky RD, Wenger JD. Should college students be vaccinated against meningococcal disease? A cost-benefit analysis. Am J Public Health. 1995;85(6):843-5. PubMed
Jackson LA, Schuchat A, Reeves MW, Wenger JD. Serogroup C meningococcal outbreaks in the United States: an emerging threat. JAMA. 1995;273(5):383-9. PubMed
Jackson LA, Tenover FC, Baker C, Plikaytis BD, Reeves MW, Stocker SA, Weaver RE, Wenger JD. Prevalence of Neisseria meningitidis relatively resistant to penicillin in the United States, 1991. Meningococcal Disease Study Group. J Infect Dis. 1994;169(2):438-41. PubMed
Issues in the control of outbreaks of group C meningococcal disease in the United States. Wenger JD, Jackson LA, Raj P, Tonelli MJ. Infect Dis Clin Practice. 1994;3:136-140. PubMed
Jackson LA, Perkins BA, Wenger JD. Cat scratch disease in the United States: an analysis of three national databases. Am J Public Health. 1993;83(12):1707-11. PubMed
Jackson LA, Wenger JD and the Meningococcal Disease Study Group. Laboratory-based surveillance for meningococcal disease in selected areas, United States, 1989-1991. CDC Surveillance Summaries, June 4, 1993. MMWR 1993;42:(No. SS-2):21-30. PubMed
Jackson LA, Kaufmann AF, Adams WG, Phelps MB, Andreasen C, Langkop CW, Francis BJ, Wenger JD. Outbreak of leptospirosis associated with swimming. Pediatr Infect Dis J. 1993;12(1):48-54. PubMed
News
Researchers begin trial for high-dose flu vaccine
KPWHRI is seeking volunteers ages 50 to 64 who have not received this season’s flu vaccine to join the trial.
News
Vaccine program recruiting volunteers in Seattle area
KPWHRI’s vaccine registry was the first to enroll participants in a clinical trial of a COVID-19 vaccine.
News
Clinical trial will evaluate mpox vaccine for adolescents
The NIH-sponsored trial will help inform decisions about vaccine approval for 12- to 17-year-olds.
Volunteers needed
Researchers begin trial for mRNA flu vaccine
The investigational vaccine is in the third phase of trials and targets flu strains expected to circulate this winter.
Research
New study confirms safety of shingles vaccine
KPWHRI researchers analyzed data from more than 640,000 vaccine doses to understand risk of severe reactions.
Land Acknowledgment
Our Seattle offices sit on the occupied land of the Duwamish and by the shared waters of the Coast Salish people, who have been here thousands of years and remain. Learn about practicing land acknowledgment.